B+
Bull case
25%
Probability
Target price
$30.00
+76.4% vs current
CBIO
Crescent BiopharmaBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$18.00
+5.9% vs current
B-
Bear case
30%
Probability
Target price
$10.00
-41.2% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+58.3
Score
AI commentary
Sentiment is cautiously constructive but still speculative. The February 26, 2026 update gave Crescent a clearer operating roadmap: ASCEND has started, CR-002 is aiming for a mid-2026 IND, more trials are planned in 2026, and management says cash of $213.2 million should fund operations into 2028 [#PR-2026-02-26] [#8-K-2026-02-26]. But forward visibility remains limited because the key proof-of-concept data do not begin until Q1 2027, and the deterministic score bundle still points to neutral-to-soft near/intermediate returns rather than a strong positive setup.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystCR-002 IND submission target in mid-2026High impact
Management said Crescent is on track to submit an IND for CR-002 in mid-2026 to support a Phase 1/2 trial in solid tumors in the second half of 2026; hitting that filing would be the next concrete pipeline de-risking step for a company still early in clinical execution [#PR-2026-02-26] [#8-K-2026-02-26].
2026-09-30eventAdditional 2026 trial starts across CR-001/CR-002High impact
Crescent said the ASCEND Phase 1/2 trial for CR-001 is underway, three additional trials are expected to initiate in 2026, and the first Phase 1/2 ADC combination trial with CR-001 is expected in the second half of 2026; any slip here would likely pressure sentiment because the current thesis rests on milestone delivery rather than revenue [#PR-2026-02-26].
2027-03-31catalystInitial proof-of-concept data beginning Q1 2027High impact
The clearest value-creation hook is management's guidance for multiple clinical data readouts beginning in Q1 2027, including initial ASCEND safety, PK/PD, and preliminary antitumor activity; positive early data could materially re-rate shares, but this remains low-visibility and high-risk today [#PR-2026-02-26].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology